A new KFF issue brief lays out key factors for the successful rollout of COVID-19 vaccinations for younger children, ages 5 to 11. This week, the Food and Drug Administration’s (FDA) advisory committee will meet to vote on a request to authorize the Pfizer vaccine for younger children. A final FDA decision, and Centers for…More
